| Literature DB >> 35213021 |
Pablo Herrero-Hernandez1,2,3, Atze J Bergsma1,2,3, W W M Pim Pijnappel4,5,6.
Abstract
Alternative pre-mRNA splicing can be cell-type specific and results in the generation of different protein isoforms from a single gene. Deregulation of canonical pre-mRNA splicing by disease-associated variants can result in genetic disorders. Antisense oligonucleotides (AONs) offer an attractive solution to modulate endogenous gene expression through alteration of pre-mRNA splicing events. Relevant in vitro models are crucial for appropriate evaluation of splicing modifying drugs. In this chapter, we describe how to investigate the splicing modulating activity of AONs in an in vitro skeletal muscle model, applied to Pompe disease. We also provide a detailed description of methods to visualize and analyze gene expression in differentiated skeletal muscle cells for the analysis of muscle differentiation and splicing outcome. The methodology described here is relevant to develop treatment options using AONs for other genetic muscle diseases as well, including Duchenne muscular dystrophy, myotonic dystrophy, and facioscapulohumeral muscular dystrophy.Entities:
Keywords: Antisense oligonucleotides; Human iPSC; In vitro models; Skeletal muscle; Splicing
Mesh:
Substances:
Year: 2022 PMID: 35213021 DOI: 10.1007/978-1-0716-2010-6_15
Source DB: PubMed Journal: Methods Mol Biol ISSN: 1064-3745